BIO's Letters, Comments and Statements on 2018 Farm Bill

The following are letters, comments and statements the Biotechnology Innovation Organization wrote, organized or signed on to with regards to negogiations on the 2018 Farm Bill. 

BIO Applauds Inclusion of Pro-Growth Provisions in Tax and Oversight Legislation

“I applaud Chairman Brady and his colleagues on the House Ways & Means Committee for recognizing the unintended consequences faced by far too many small business innovators today due to NOL limitations."

Clinical Trials: BIO Comments on FDA Draft Guidance : Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics

November 28, 2018


Clinical Trials: BIO Comments on FDA Draft Guidance Adaptive Designs for Clinical Trials of Drugs and Biologics


21st Annual BIO CEO & Investor Conference Programming Announced

The Biotechnology Innovation Organization (BIO) today announced preliminary programming for the upcoming BIO CEO & Investor Conference to be held February 11-12, 2019 in New York City. Program lineup covers policy, investment, innovation and patient access. New this year, BIO is offering Executive Leadership courses to help companies develop tools for striking deals and improving corporate reputation. Participants will choose between one of two interactive courses which are based on real-life biopharma experiences and will run on Sunday, February 10.

BIO Statement on Unsubstantiated Reports of Heritable Human Genome Editing Experiments in China

The Biotechnology Innovation Organization (BIO) issued the following statement regarding unsubstantiated reports this week of experiments involving heritable human genome editing in China.

BIO Welcomes 21 New Companies to Industrial & Environmental Section

The Biotechnology Innovation Organization today announced 21 companies have joined the Industrial & Environmental Section over the past year. BIO will work closely with these diverse new members as it continues to lead advocacy efforts that advance the development and adoption of biotechnology into industrial and environmental processes, such as the production of bio-based products and biofuels.

BIO Statement on Proposed Changes to Medicare Advantage and Part D Plans

“Today’s proposed rule to roll back critical protections afforded to some of America’s sickest and most vulnerable Medicare beneficiaries would, if adopted, severely limit seniors’ access to the drugs most appropriate for them, and is yet another unfortunate example of Administration proposals that will financially benefit insurance plans and other middlemen in the drug supply chain at the expense of patients."

DSCSA: BIO files Comments on FDA Draft Guidance Product Identifiers Under the Drug Supply Chain Security Act Questions and Answers

November 19, 2018


New Report Shows Global Link Between Pro-Innovation Policies and Biotech Advances

Washington, D.C. (November 19, 2018) – A study released today highlights strategies, policies and best practices that have been successful in...